Asieris Pharmaceuticals 2022 Semi-annual Report: Rapid clinical advancement worldwide, and steady implementation of the integrated commercialization strategy of diagnosis and treatment

SHANGHAI, Aug.

Rapid advancement of core clinical projects, strengthening the global distribution of pipelines

In the field of reproductive system diseases, APL-1702 (trade name: Sevita®), the core product of photodynamic therapy developed by Asieris, which integrates drugs and devices, has received international multi-center Phase III clinical trials in China, Hungary, Approved by national drug regulatory agencies of Ukraine, Germany, Slovakia, Czech Republic, Netherlands, Poland and other countries and enrolled patients, the enrollment of all subjects will be completed in July 2022

APL-1202 (trade name: Vishke®), a core product independently developed by Asieris in the field of urological diseases, is used in a clinical trial of oral combination with tislelizumab as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).

In the field of urological diseases, another core product of Asieris, APL-1706 (trade name: Hikeway®), obtained the approval notice for Phase III clinical trials conducted by the State Drug Administration in February 2022, and obtained the CDE in March 2022.

Asieris Pharma launches its first integrated bladder cancer diagnosis and treatment center, steadily advancing its commercialization strategy

Based on the integration of diagnosis and treatment in the field of genitourinary tumors, Asieris has built an advantageous product portfolio covering bladder cancer diagnosis, treatment and follow-up and has gradually implemented it

Expansion of R&D scale and perfect incentive mechanism

Asieris' R&D scale continues to expand, and its core innovation and competitiveness continue to increase

Dr.

About Asieris

Asieris (stock code: 688176.

The company adheres to the core driving force of innovative technologies and products, and through building its own R&D platform and core technologies, in-depth exploration of the mechanism of drug action, and efficient screening and evaluation of candidate drugs

At the same time, through independent research and development and strategic cooperation, Asieris Pharma conducts an in-depth layout of product pipelines around urogenital diseases, pays close attention to the technological frontiers and treatment development trends in this field, provides insight into and taps unmet clinical needs, and conducts forward-looking progress.

Source: Asieris